{"id":"W4401612362","doi":"10.1016/j.medj.2024.07.022","title":"Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial","year":2024,"lang":"en","type":"article","venue":"Med","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Fondation du cancer des Cèdres; Eisai; MacroGenics; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Clovis Oncology; Novocure; Regeneron Pharmaceuticals; National Center for Research Resources; Karyopharm Therapeutics; Merck; GlaxoSmithKline; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Ovarian cancer; Oncology; Chemotherapy; Clinical trial; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001333687,0.0001579724,0.0005692963,0.00008358066,0.0000156362,0.0000111031,0.00002865811,0.00009395913,0.0002669185],"category_scores_gemma":[0.00002596001,0.0001164555,0.0001377306,0.0001273815,0.00006343929,0.0000431287,0.000003668081,0.00007811461,0.000002833065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001434769,"about_ca_system_score_gemma":0.0004258026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001280043,"about_ca_topic_score_gemma":0.0005912705,"domain_scores_codex":[0.9986055,0.00005113086,0.0006093115,0.0004138487,0.0001781643,0.0001420585],"domain_scores_gemma":[0.9993185,0.0002906649,0.00006372619,0.0001943364,0.00002456727,0.0001081426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2787001,0.003629814,0.005904758,0.00003730427,0.0007284294,0.0002196824,0.002426669,0.00002946201,0.000203224,0.0001197881,0.0004089136,0.7075919],"study_design_scores_gemma":[0.8423856,0.004780274,0.104181,0.0003970712,0.0004230225,0.00000483151,0.00004194045,0.003922559,0.00136473,0.0002773429,0.04207271,0.0001488699],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9755588,0.00914937,0.00004061984,0.01242439,0.0005532841,0.001107427,0.0008910977,0.00003422368,0.0002407548],"genre_scores_gemma":[0.9910726,0.00588187,0.001506973,0.0001013128,0.0006379632,0.0002204955,0.0003068416,0.00002174324,0.0002501917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7074431,"threshold_uncertainty_score":0.4748918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05318943154343298,"score_gpt":0.4073210919774259,"score_spread":0.3541316604339929,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}